We serve Chemical Name:3-(4-Bromophenyl)pyrrolidine CAS:328546-98-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(4-Bromophenyl)pyrrolidine
CAS.NO:328546-98-1
Synonyms:3-(4-Bromophenyl)pyrrolidine;Pyrrolidine,3-(4-bromophenyl);Pyrrolidine, 3-(4-bromophenyl)-;3-(4-BROMO-PHENYL)-PYRROLIDINE;3-(4-Bromophenyl)pyrrolidine HCl
Molecular Formula:C10H12BrN
Molecular Weight:226.113
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:293.4±33.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.567
PSA:12.03000
Exact Mass:225.015305
LogP:2.44
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(4-Bromophenyl)pyrrolidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(4-Bromophenyl)pyrrolidine HCl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrrolidine,3-(4-bromophenyl) Use and application,Pyrrolidine, 3-(4-bromophenyl)- technical grade,usp/ep/jp grade.
Related News: The company’s contract arm churns out more than 250 metric tons of commercial APIs every year for injectables, inhalables, highly potent, cytotoxic and controlled substances, according to a release. N-2-4-DNP-L-ASPARAGINE CRYSTALLINE manufacturers Wavelength, a more than 30-year-old firm based in Petah Tikva, launched its API CDMO business in early 2020 and currently sports more than 250 customers from 50 countries. Opine/octopine dehydrogenase (Agrobacterium tumefaciens strainC58 gene Atu5418) suppliers GSK picked McNamara after six months of “extensive search and selection process,” GSK said in its announcement Thursday. It ran the quest with help from two headhunters and evaluated “several external and internal candidates,” it said. N-thiobenzoyl-DL-valine vendor & factory In the US, avalglucosidase alfa saw its PDUFA date pushed back by three months, from May 18 to Aug. 18, according to a Sanofi investor presentation in April.,The vaccine has been through the ringer over safety worries before. In April, U.S. authorities halted its use and later tagged it with a warning over reports of rare blood clots occurring alongside bleeding in some recipients.
